Intravitreal Injections

Intravitreal injections are a crucial treatment modality in ophthalmology, primarily used to deliver medications directly into the vitreous cavity of the eye. This technique is particularly effective in managing various sight-threatening conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and macular edema. By bypassing the blood-retinal barrier, intravitreal injections ensure high concentrations of medications reach the target site, maximizing therapeutic efficacy while minimizing systemic side effects.

Common medications administered via intravitreal injection include anti-vascular endothelial growth factor (anti-VEGF) agents like ranibizumab and aflibercept, which help inhibit abnormal blood vessel growth and reduce fluid leakage in the retina. Corticosteroids such as dexamethasone implants are also used to suppress inflammation and edema. While generally safe, intravitreal injections carry risks of complications such as infection, retinal detachment, or intraocular pressure elevation, necessitating careful patient monitoring. Overall, these injections represent a pivotal advancement in managing retinal diseases, offering many patients significant visual improvement and preservation.